AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01141374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by needles
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
Study NCT01141374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by seeds
Description: We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
Study NCT04253366 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clinical investigation device class IIa not marked CE
Description: Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
Study NCT04255420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPG Block
Description: A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.
Study NCT04255420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Treatment
Description: Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
Study NCT03100084 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling
Study NCT04045925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taïso
Description: Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
Study NCT02618577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
Study NCT02618577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.
Study NCT03597256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Intradermal injection
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: 50 mg capsules
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: 2 mg/mL oral solution
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 MG
Description: 1 mg tablet
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: 500 mg tablet
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg tablet
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: 0.25 mg tablet
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil Tablets
Description: 600 mg tablet
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 100 mg capsule
Study NCT04008186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Pill
Description: 120 mg tablet
Study NCT04393012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide alternative nurse call and communication device
Description: Evaluate impact of providing access to the nurse call system and a speech generating device.
Study NCT01848808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wobenzym PS
Study NCT01848808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00571090 — intervention group
Intervention type: PROCEDURE
Intervention: Thyroid ultrasonography
Description: Ultrasound-guided thyroid fine-needle aspiration biopsy
Study NCT01817478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microbiologic sample
Study NCT01989273 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound of inferior vena cava
Study NCT04737694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Oral ketone ester + glucose supplement
Study NCT04737694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose supplement
Study NCT02641353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Tablet
Description: 30 mg tablet
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life (EQ-5D-5L) Questionnaire
Description: The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: PROMIS Cognitive Function 4a Questionnaire
Description: The PROMIS measures function, symptoms, behavior and feelings.
Study NCT02641353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Suspension
Description: 30 mg oral suspension
Study NCT01198548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01198548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01198548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study NCT01198548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01198548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01198548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04721262 — intervention group
Intervention type: DEVICE
Intervention: Hyperfine Portable MRI
Description: The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
Study NCT02797730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art-therapy sessions
Study NCT00504309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks
Study NCT00504309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks
Study NCT00504309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks
Study NCT04319237 — intervention group
Intervention type: BEHAVIORAL
Intervention: Comprehensive Score for Financial Toxicity (COST) measure
Description: The COST is a questionnaire made up of 11 statements around topics including costs, concerns and resources and is designed to measure financial toxicity. The user answers questions about their concern over finances numbered from 0-4, with 0 being not at all and 4 being very much.
Study NCT03913416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed model
Description: Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
Study NCT03913416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group is composed of patients operated with standard surgery
Study NCT00667030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and aerobic exercise training
Description: Weight loss and aerobic exercise training
Study NCT03306381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Elimination of certain products.
Study NCT03888274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearUP Sinus Pain Relief
Description: Microcurrent Device Treatment
Study NCT00649948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fed
Study NCT00649948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage XR 500 mg
Description: 500mg, single dose fed
Study NCT02517229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02517229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: balance control measurements
Study NCT02517229 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: electromagnetic maneuverable postural platform
Study NCT01292538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia GLS
Description: 532 nm green diode low level laser light device
Study NCT01292538 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo laser
Description: Sham light output with no therapeutic benefit
Study NCT05150288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
Study NCT00508846 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two-part telephone questionnaire lasting about 60 minutes total.
Study NCT01849809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Ventral Capsulotomy
Study NCT00724503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres yttrium-90 microspheres
Description: SIR-Spheres microspheres (yttrium-90 \[Y-90\] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2.
Study NCT00724503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy (FOLFOX)
Description: mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2.
Study NCT04979013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers will be switched to smoking abstinence for 14 days
Study NCT02608606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: compared oral administration versus sublingual administration of tacrolimus.
Study NCT02777788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JinFuKang
Description: treated with chemotherapy
Study NCT02777788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XingZaoRuanJian
Description: treated with chemotherapy
Study NCT02777788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin
Study NCT01893008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable).
Study NCT03401333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging and Brief Negotiation Interview
Description: An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
Study NCT04645108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight and physical activity on a weekly basis, and meals daily.
Study NCT04645108 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Noom Healthy Weight; mobile behavior change program for weight loss
Description: The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity. During the first week of the study, participants will be introduced to the program, and the Noom app.
Study NCT01990781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD: Lidocaine and dexamethasone
Description: LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
Study NCT01990781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L:Lidocaine
Description: Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
Study NCT01990781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D: Dexamethasone
Description: D:intravenous dexamethasone 8 mg before induction of anesthesia
Study NCT01990781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N: Normal saline (placebo)
Description: Normal saline: 2ml
Study NCT00985374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 5mg or 10mg po daily
Study NCT00985374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: 16mg/kg iv every 3 weeks
Study NCT02803541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 day mainstream summer camp experience
Description: see arm description
Study NCT02937922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AEROBIC
Description: The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: \[(HR max - HR rest) x desired intensity\] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
Study NCT02937922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RESISTANCE
Description: The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60 % of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
Study NCT02937922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMBINED
Description: The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
Study NCT01301092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: administered intravenous, subcutaneous or intramuscular
Study NCT04264585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy
Description: All clients will receive the same materials, namely the UniWellbeing Course, which was developed at Macquarie University, Australia. The UniWellbeing Course is a transdiagnostic intervention targeting symptoms of depression and anxiety, that has been tailored for use in post-secondary students. It comprises 4 online lessons that provide psychoeducation about: symptom identification and the cognitive behavioural model; thought monitoring and challenging; de-arousal strategies and pleasant activity scheduling; graduated exposure; and relapse prevention. Seven supplementary lessons can also be accessed at any time (e.g., sleep, communication). Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) with 4 lesson summaries and homework assignments that facilitate skill acquisition. Therapists will spend \~15 mins. per week/per client.
Study NCT02140580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surfactant therapy
Description: Active Comparator
Study NCT04264585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Clients assigned to the ICBT with Motivational Interviewing condition will receive access to the Planning for Change lesson before accessing Lesson 1. They will be presented with five interactive online exercises based on motivational interviewing principles (i.e. values clarification, importance ruler, looking back, confidence ruler, and looking forward). As clients complete the exercises, they are prompted to answer open-ended questions and are provided with written feedback.
Study NCT02140580 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuation on CPAP
Description: Sham Comparator
Study NCT00840216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500 mg tablets
Description: 1 x 500 mg